Holen Sie sich die Stockscreener-App
135.49
3.03%
3.98
Schlusskurs vom Vortag:
$131.51
Offen:
$132.89
24-Stunden-Volumen:
283.21K
Relative Volume:
0.91
Marktkapitalisierung:
$1.60B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+5.36%
1M Leistung:
+65.21%
6M Leistung:
+150.26%
1J Leistung:
+554.54%
1-Tages-Spanne:
$130.53
$138.00
1-Wochen-Bereich:
$127.65
$151.18
52-Wochen-Spanne:
$18.23
$151.18
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
(484) 253-1461
Adresse
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
135.49 | 1.56B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Mizuho | Outperform |
| 2025-12-05 | Eingeleitet | BTIG Research | Buy |
| 2025-12-04 | Eingeleitet | Craig Hallum | Buy |
| 2025-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-06 | Eingeleitet | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-04-09 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-26 | Eingeleitet | Stifel | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-05 | Eingeleitet | TD Cowen | Buy |
| 2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Eingeleitet | Jefferies | Buy |
| 2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
| 2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Update - MarketBeat
Palvella Reports Phase 3 Success for QTORIN in Rare Skin Disorder - MyChesCo
Palvella Therapeutics raises $230M in upsized stock offering By Investing.com - Investing.com Canada
Palvella Therapeutics raises $230M in upsized stock offering - Investing.com Australia
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares - Investing.com UK
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares By Investing.com - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Director Elaine Heron Purchases 2,400 Shares - MarketBeat
Insider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Acquires 4,000 Shares of Stock - MarketBeat
Palvella Therapeutics Insider Bought Shares Worth $300,000, According to a Recent SEC Filing - marketscreener.com
Palvella therapeutics (PVLA) director buys $500k in stock - Investing.com
Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple - Yahoo Finance
Palvella raises $230M to develop rare skin disease drugs - Stock Titan
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
PVLA PE Ratio & Valuation, Is PVLA Overvalued - Intellectia AI
Palvella Therapeutics Announces Underwritten Common Stock Offering - The Globe and Mail
PVLA Stock Surges 86% With A 6-day Winning Spree On Phase 3 Win - Trefis
Palvella prices $200M stock offering at $125 per share - Investing.com Australia
Strategic Update: PVLA Surges Amid New Growth Plans - timothysykes.com
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up After Analyst Upgrade - MarketBeat
Palvella Therapeutics shares rise to three-year high on upsized offering - Investing.com UK
Assessing Palvella Therapeutics (PVLA) Valuation After Its Recent Share Price Surge - simplywall.st
What is Lifesci Capital's Estimate for PVLA FY2026 Earnings? - MarketBeat
HC Wainwright Has Optimistic Outlook of PVLA FY2027 Earnings - MarketBeat
Palvella Therapeutics, Inc. (PVLA) Stock Analysis: A Potential 74% Upside in the Biotech Sector - DirectorsTalk Interviews
Palvella Therapeutics announces pricing of upsized public offering - marketscreener.com
Palvella Therapeutics Announces Pricing of Upsized Public Offering - Bitget
Palvella Therapeutics Announces Pricing Of Upsized Public Offering - TradingView
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $250.00 at Mizuho - MarketBeat
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright - Yahoo Finance
BTIG Research Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $215.00 - MarketBeat
Palvella launches $150M public stock offering - Investing.com India
Palvella prices $200M stock offering at $125 per share By Investing.com - Investing.com Canada
Palvella Therapeutics Shares Jump as Phase 3 SELVA Trial Hits Primary Endpoint for QTORIN Rapamycin - MarketBeat
Aug Big Picture: Is Innovative Solutions and Support Inc showing insider buyingPortfolio Risk Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Palvella Therapeutics announces proposed public offering - marketscreener.com
Palvella Therapeutics Launches $150 Million Public Offering - marketscreener.com
Palvella Therapeutics Stock Takes a Dive Amidst Market Flux - timothysykes.com
Palvella Therapeutics stock hits 52-week high at 115.95 USD By Investing.com - Investing.com South Africa
Palvella launches $150M public stock offering By Investing.com - Investing.com UK
Palvella Therapeutics Announces Proposed Public Offering - The Manila Times
Strategic Acquisition Expands PVLA’s Market Reach in Europe - StocksToTrade
Truist raises Palvella Therapeutics stock price target on phase 3 data - Investing.com Australia
TD Cowen raises Palvella Therapeutics price target on phase 3 data - Investing.com Canada
Chardan Capital Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $210.00 - MarketBeat
Global Pharma Merger: PVLA’s Game-Changer - timothysykes.com
Stifel raises Palvella Therapeutics price target on trial results By Investing.com - Investing.com Canada
Novo to cut GLP-1 drug prices; Palvella soars on study data - BioPharma Dive
Bladder phase II sinks Protara, LMs phase III wins for Palvella - BioWorld MedTech
Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year HighTime to Buy? - MarketBeat
Palvella stock surges on late-stage trial win (PVLA:NASDAQ) - Seeking Alpha
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):